V 2 C-Driven Nanodelivery Platform Potentiates Synergistic Breast Cancer Therapy

作者：Sijie Wu, Shuang Du, Yucheng Guan, Quanshi Lin, Yan Liu, Runlin Lv, Zhenlin Zhang, Yong Xia, Tongkai Chen, Honghai Hong · 发表于：ACS Materials Letters · 年份：2023 · DOI：10.1021/acsmaterialslett.3c00965 · 被引用次数：11 · 研究领域：Nanoplatforms for cancer theranostics、Advanced Nanomaterials in Catalysis、Extracellular vesicles in disease

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Conventional therapies for TNBC are limited by several drawbacks, including poor therapeutic efficacy and adverse effects. In contrast, photothermal therapy (PTT) has shown advantages in the treatment of TNBC due to its ease of administration and safe profile. Vanadium carbide (V 2 C), a new type of two-dimensional nanomaterial used in biomedicine, has shown excellent photothermal conversion and drug-carrying properties and has proven to be safe owing to its biodegradable characteristics. Therefore, in this study, the chemotherapeutic drug doxorubicin (Dox) was loaded onto V 2 C to prepare a new nanocomposite (V 2 C–Dox nanosheets). PTT with V 2 C–Dox induced localized therapeutic thermal effects and prompted drug release. V 2 C and V 2 C–Dox nanosheets alone were nontoxic to breast cancer cells. However, Dox, V 2 C+laser, and V 2 C–Dox+laser significantly inhibited the viability, clonogenic ability, and migration of breast cancer cells and induced their apoptosis, with V 2 C–Dox+laser having the strongest effect. In addition, combined transcriptomic and metabolomic analyses indicated that the amino acid biosynthesis pathway and the ferroptosis pathway resulting from the aberrant expression of SLC7A11, PED4D, and 2-oxo-4-hydroxy-4-carboxy-5-uronium imidazoline may be involved in the antibreast cancer effects of V 2 C–Dox after irradiation. Experiments in a breast cancer xenograft model showed that V ...